Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

CRSIPR Therapeutics (CRSP) is expected to update its pipeline candidates, specifically exa-cel, its lead candidate, in its third-quarter earnings.

BMRNPositive Net Change VRTXPositive Net Change EDITPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why

Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end

RHHBYNegative Net Change SRPTNegative Net Change KMDAPositive Net Change

Zacks Equity Research

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

VRTXPositive Net Change CRSPNegative Net Change SESNPositive Net Change